Qianjiang Yongan Pharmaceutical Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	7.8yrs
Promedio de permanencia en la Junta Directiva	6.1yrs

Actualizaciones recientes de la dirección

Recent updates

Investors Aren't Buying Qianjiang Yongan Pharmaceutical Co., Ltd.'s (SZSE:002365) Revenues

Feb 27

CEO

Qianjiang Yongan Pharmaceutical no tiene CEO, o no tenemos datos al respecto.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ding Hongli	Deputy GM & Director	12.2yrs	CN¥1.28m	0.11% CN¥ 2.4m
Baineng Luo	Head of the Audit Department	7.8yrs	CN¥633.80k	0.061% CN¥ 1.3m
Songlin Mei	Head of the Supply Department	7.8yrs	CN¥629.40k	0.064% CN¥ 1.4m
Xiangzhen Dai	Executive Officer	7.8yrs	CN¥639.20k	0.061% CN¥ 1.3m
Shaobo Li	Senior Management	5.4yrs	CN¥931.40k	0.017% CN¥ 357.4k
Shi Hao Dong	Deputy General Manager	18.3yrs	CN¥1.90m	0.37% CN¥ 7.8m
Zhihua Wang	Deputy General Manager	9.1yrs	CN¥1.16m	0.095% CN¥ 2.0m
Xiaobo Wu	Deputy General Manager	3.1yrs	CN¥856.80k	0.095% CN¥ 2.0m
Xiquan Fang	Deputy General Manager	11yrs	CN¥1.62m	0.095% CN¥ 2.0m

7.8yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 002365 es experimentado (7.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ding Hongli	Deputy GM & Director	12.2yrs	CN¥1.28m	0.11% CN¥ 2.4m
Yong Chen	Chairman	18.3yrs	CN¥3.76m	21.54% CN¥ 458.2m
Wu Yuxi	Chairman of the Supervisory Board	3.1yrs	CN¥166.70k	0.19% CN¥ 4.0m
Chunxiang Zhao	Independent Director	3.1yrs	CN¥80.00k	sin datos
Bing Zhang	Independent Director	3.1yrs	CN¥40.00k	sin datos
Xu Wu	Supervisor	9.1yrs	sin datos	sin datos

6.1yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de 002365 se considera experimentada (5.8 años de antigüedad promedio).

Qianjiang Yongan Pharmaceutical Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Qianjiang Yongan Pharmaceutical Co., Ltd., Annual General Meeting, Jun 21, 2024

Less than half of directors are independent

Recent updates

Insufficient new directors

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Qianjiang Yongan Pharmaceutical Co., Ltd., Annual General Meeting, Jun 21, 2024

First quarter 2024 earnings released: EPS: CN¥0.097 (vs CN¥0.051 in 1Q 2023)

Full year 2023 earnings released: CN¥0.042 loss per share (vs CN¥0.48 profit in FY 2022)

Investor sentiment deteriorates as stock falls 16%

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Investors Aren't Buying Qianjiang Yongan Pharmaceutical Co., Ltd.'s (SZSE:002365) Revenues

Investor sentiment deteriorates as stock falls 27%

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 19, 2024

Third quarter 2023 earnings released: CN¥0.034 loss per share (vs CN¥0.15 profit in 3Q 2022)

New minor risk - Profit margin trend

Full year 2022 earnings released: EPS: CN¥0.48 (vs CN¥0.38 in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.13 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.13 in 2Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.07 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.32 in 2Q 2020)

Qianjiang Yongan Pharmaceutical Co., Ltd. (SZSE:002365) completed the acquisition of 35% stake in Wuhan Low-dimensional Materials Research Institute Co., Ltd. from Li Ganghui and Wuhan Xinlian Huida Technology Investment Partnership (Limited Partnership).

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.027 (vs CN¥0.017 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.37 (vs CN¥0.31 in FY 2019)

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥8.66

New 90-day low: CN¥9.00

New 90-day low: CN¥10.03

New 90-day low: CN¥10.32

Third quarter earnings released

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 23, 2020

New 90-day low: CN¥11.10

New 90-day low: CN¥11.63

Earnings released

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

CEO

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad